Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Cardiology Reports
Published in: Current Cardiology Reports 2/2012

01-04-2012 | Peripheral Vascular Disease (M Shishehbor, Section Editor)

Current State of Diagnosis and Management of Critical Limb Ischemia

Authors: Dan Clair, Samir Shah, John Weber

Published in: Current Cardiology Reports | Issue 2/2012

Login to get access

Abstract

Critical limb ischemia represents the most severe form of peripheral arterial disease and carries with it severe morbidity and mortality risks. Because of comorbidity risks, early diagnosis and aggressive medical management make up an important part of the treatment paradigm for these individuals. However, in addition to managing these comorbid conditions, the physician caring for these individuals must be able to provide revascularization options that will improve arterial flow to the threatened extremity and assure healing of complicated wounds. Both open surgical and endovascular therapies have proven beneficial in restoring flow to severely ischemic limbs in these patients. Additionally, combinations of the above therapeutic methods have offered more available options for these patients. This article reviews care of patients with critical limb ischemia with critical assessment of options for medical and revascularization options.
Literature
1.
Ostchega Y, Paulose-Ram R, Dillon CF, et al. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004. J Am Geriatr Soc. 2007;55:583–9.PubMedCrossRef
2.
Lepantalo M, Matzke S. Outcome of unreconstructed chronic critical leg ischaemia. Eur J Vasc Endovasc Surg. 1996;11:153–7.PubMedCrossRef
3.
Wolfe JH, Wyatt MG. Critical and subcritical ischaemia. Eur J Vasc Endovasc Surg. 1997;13:578–82.PubMedCrossRef
4.
Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000;31:S1–S296.PubMedCrossRef
5.
6.
Bettmann MA, Heeren T, Greenfield A, Goudey C. Adverse events with radiographic contrast agents: results of the SCVIR Contrast Agent Registry. Radiology. 1997;203:611–20.PubMed
7.
Waugh JR, Sacharias N. Arteriographic complications in the DSA era. Radiology. 1992;182:243–6.PubMed
8.
Lundin P, Svensson A, Henriksen E, et al. Imaging of aortoiliac arterial disease. Duplex ultrasound and MR angiography versus digital subtraction angiography. Acta Radiol. 2000;41:125–32.PubMedCrossRef
9.
Kreitner KF, Kalden P, Neufang A, et al. Diabetes and peripheral arterial occlusive disease: prospective comparison of contrast-enhanced three-dimensional MR angiography with conventional digital subtraction angiography. AJR Am J Roentgenol. 2000;174:171–9.PubMed
10.
Heijenbrok-Kal MH, Kock MC, Hunink MG. Lower extremity arterial disease: multidetector CT angiography meta-analysis. Radiology. 2007;245:433–9.PubMedCrossRef
11.
•• Gandhi S, Weinberg I, Margey R, and Jaff MR. Comprehensive medical management of peripheral arterial disease. Prog Cardiovasc Dis 2011, 54:2-13. The authors provide an extensive and current review of all aspects of the medical management of these complex patients. Topics include all aspects of the management of these patients and an understanding of these concepts is critical to those caring for these patients.
12.
Abraira C, Duckworth WC, Moritz T. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes Obes Metab. 2009;11:150–6.PubMedCrossRef
13.
Standards of medical care in diabetes—2010. Diabetes Care 2010, 33 Suppl 1:S11-61.
14.
Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007, 45:645-654; discussion 653-644.
15.
Mohler 3rd ER, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108:1481–6.PubMedCrossRef
16.
Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006, 113:e463-654.
17.
Willigendael EM, Teijink JA, Bartelink ML, et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg. 2004;40:1158–65.PubMedCrossRef
18.
Price JF, Mowbray PI, Lee AJ, et al. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J. 1999;20:344–53.PubMedCrossRef
19.
Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Bmj. 2000;321:412–9.PubMedCrossRef
20.
Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–53.PubMedCrossRef
21.
Fox KM, Henderson JR, Bertrand ME, et al. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA). Eur Heart J 1998, 19 Suppl J:J52-5.
22.
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Bmj 2002, 324:71-86.
23.
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996, 348:1329-39.
24.
Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–17.PubMedCrossRef
25.
Belch JJ, Dormandy J, Biasi GM, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010, 52:825-833, 833 e821-822.
26.
Zukauskas G, Ulevicius H, Janusauskas E. An optimal inflow procedure for multi-segmental occlusive arterial disease: ilio-femoral versus aorto-bifemoral bypass. Cardiovasc Surg. 1998;6:250–5.PubMedCrossRef
27.
Carsten 3rd CG, Kalbaugh CA, Langan 3rd EM, et al. Contemporary outcomes of iliofemoral bypass grafting for unilateral aortoiliac occlusive disease: a 10-year experience. Am Surg. 2008;74:555–9. discussion 559-560.PubMed
28.
Chiu KW, Davies RS, Nightingale PG, et al. Review of direct anatomical open surgical management of atherosclerotic aorto-iliac occlusive disease. Eur J Vasc Endovasc Surg. 2010;39:460–71.PubMedCrossRef
29.
Mingoli A, Sapienza P, Feldhaus RJ, et al. Comparison of femorofemoral and aortofemoral bypass for aortoiliac occlusive disease. J Cardiovasc Surg (Torino). 2001;42:381–7.
30.
Thuijls G, van Laake LW, Lemson MS, Kitslaar PJ. Usefulness and applicability of femorofemoral crossover bypass grafting. Ann Vasc Surg. 2008;22:663–7.PubMedCrossRef
31.
Kim YW, Lee JH, Kim HG, Huh S. Factors affecting the long-term patency of crossover femorofemoral bypass graft. Eur J Vasc Endovasc Surg. 2005;30:376–80.PubMedCrossRef
32.
Mii S, Eguchi D, Takenaka T, et al. Role of femorofemoral crossover bypass grafting for unilateral iliac atherosclerotic disease: a comparative evaluation with anatomic bypass. Surg Today. 2005;35:453–8.PubMedCrossRef
33.
Aburahma AF, Robinson PA, Cook CC, Hopkins ES. Selecting patients for combined femorofemoral bypass grafting and iliac balloon angioplasty and stenting for bilateral iliac disease. J Vasc Surg. 2001;33:S93–99.PubMedCrossRef
34.
Ricco JB, Probst H. Long-term results of a multicenter randomized study on direct versus crossover bypass for unilateral iliac artery occlusive disease. J Vasc Surg. 2008;47:45–53. discussion 53-44.PubMedCrossRef
35.
Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007, 45 Suppl S:S5-67.
36.
Zander T, Blasco O, Rabellino M, et al. Bifurcated endograft in aortoiliac type C and D lesions: long-term results. J Vasc Interv Radiol. 2011;22:1124–30.PubMedCrossRef
37.
Nishibe T, Kondo Y, Dardik A, et al. Hybrid surgical and endovascular therapy in multifocal peripheral TASC D lesions: up to three-year follow-up. J Cardiovasc Surg (Torino). 2009;50:493–9.
38.
Leville CD, Kashyap VS, Clair DG, et al. Endovascular management of iliac artery occlusions: extending treatment to TransAtlantic Inter-Society Consensus class C and D patients. J Vasc Surg. 2006;43:32–9.PubMedCrossRef
39.
Schanzer A, Hevelone N, Owens CD, et al. Technical factors affecting autogenous vein graft failure: observations from a large multicenter trial. J Vasc Surg. 2007;46:1180–90. discussion 1190.PubMedCrossRef
40.
Conte MS. Technical factors in lower-extremity vein bypass surgery: how can we improve outcomes? Semin Vasc Surg. 2009;22:227–33.PubMedCrossRef
41.
Clark TW, Groffsky JL, Soulen MC. Predictors of long-term patency after femoropopliteal angioplasty: results from the STAR registry. J Vasc Interv Radiol. 2001;12:923–33.PubMedCrossRef
42.
Muradin GS, Bosch JL, Stijnen T, Hunink MG. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis. Radiology. 2001;221:137–45.PubMedCrossRef
43.
Kandarpa K, Becker GJ, Hunink MG, et al. Transcatheter interventions for the treatment of peripheral atherosclerotic lesions: part I. J Vasc Interv Radiol. 2001;12:683–95.PubMedCrossRef
44.
Met R, Van Lienden KP, Koelemay MJ, et al. Subintimal angioplasty for peripheral arterial occlusive disease: a systematic review. Cardiovasc Intervent Radiol. 2008;31:687–97.PubMedCrossRef
45.
Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115:2745–9.PubMedCrossRef
46.
Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267–76.PubMedCrossRef
47.
Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701–10.PubMedCrossRef
48.
Duda SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005;16:331–8.PubMedCrossRef
49.
• Lammer J, Bosiers M, Zeller T, et al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg 2011, 54:394-401. This article offers a modern-day assessment of medicated stents in patients with peripheral arterial disease and highlights some of the issues that have yet to be addressed in applying this technology to patients with vascular disease.
50.
Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689–99.PubMedCrossRef
51.
Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358–65.PubMedCrossRef
52.
Romiti M, Albers M, Brochado-Neto FC, et al. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 2008;47:975–81.PubMedCrossRef
53.
Adam DJ, Beard JD, Cleveland T, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366:1925–34.PubMedCrossRef
54.
• Conte MS. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) and the (hoped for) dawn of evidence-based treatment for advanced limb ischemia. J Vasc Surg 2010, 51:69S-75S. This is an excellent review of the BASIL trial. The author highlights the positives and shortcomings of the BASIL trial and points out how the care for patients might be advanced by further randomized studies like BASIL.
Metadata
Title
Current State of Diagnosis and Management of Critical Limb Ischemia
Authors
Dan Clair
Samir Shah
John Weber
Publication date
01-04-2012
Publisher
Current Science Inc.
Published in
Current Cardiology Reports / Issue 2/2012
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-012-0251-4

Other articles of this Issue 2/2012

Current Cardiology Reports 2/2012 Go to the issue

Peripheral Vascular Disease (M Shishehbor, Section Editor)

Management of Combined Severe Carotid and Coronary Artery Disease

Peripheral Vascular Disease (M Shishehbor, Section Editor)

Carotid Artery Stenting Versus Carotid Endarterectomy: Post CREST

Nuclear Cardiology (V Dilsizian, Section Editor)

The Potential Utility of 123I-mIBG in Atrial Fibrillation and in the Electrophysiology Laboratory

Peripheral Vascular Disease (M Shishehbor, Section Editor)

Renal Intervention to Treat Hypertension

Valvular Heart Disease (V Nkomo, Section Editor)

Tricuspid Regurgitation: Pathophysiology and Management

Nuclear Cardiology (V Dilsizian, Section Editor)

Advances in Nuclear Cardiac Instrumentation with a View Towards Reduced Radiation Exposure

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits